Fig. 4From: Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safetyIRDye800CW-nimotuzumab imaging in mice bearing HT29, MDA-MB-468 and MDA-MB-435 xenografts. IRDye800CW-nimotuzumab was injected into CD-1 nude mice bearing EGFR positive xenografts a) HT-29, b) MDA-MB-468, and an EGFR negative xenograft c) MDA-MB-435 and imaged at 72 and 168 h post injection. Scale represents the mean fluorescence intensityBack to article page